All In Biotech

Drug Trial Radar · NCT02866032

Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

Last checked: Nov 20, 2026Latest source record: Oct 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

452

Actual

Start

Sep 2016

Primary completion

Jun 10, 2020

Study completion Jun 10, 2020

Sponsor

Lead sponsor
Moberg Pharma ABIndustry
Sponsor type
Industry
First posted
Aug 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Who can join
All sexes, from 18 years, up to 75 years

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of topical MOB015B in patients with mild to moderate distal subungual onychomycosis (DSO). The secondary objective is to evaluate the safety of topical MOB015B in patients with mild to moderate DSO.

Conditions

  • Distal Subungual Onychomycosis

Interventions

  • MOB015BDrug

  • Ciclopirox 80 mg/gDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete cure of the target nail defined as negative fungal culture of dermatophytes, negative direct KOH microscopy and 0% clinical disease involvement at Week 52Time frame: Week 52

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Multiple Locations, Germany

  • Site not named

    Multiple Locations, Poland

  • Site not named

    Multiple Locations, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.